Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.

Objective: To examine the overall safety of intravenous immunoglobulin (IVIG) administered according to a clinically defined, home-based therapeutic regimen in patients with neuroimmunologic diseases.

Methods: A total of 1,085 infusions of a new liquid IVIG 10% preparation were administered to 70 patients diagnosed with neuroimmunologic diseases over a 9-month period. These infusions were retrospectively reviewed for safety and tolerability.